ライフサイエンスコーパス: levonorgestrel

1 efficacy of ulipristal acetate compared with levonorgestrel.

2 regimen (ethinyl estradiol, 100 microg, and levonorgestrel, 0.5 mg, repeated in 12 hours).

3 The levonorgestrel-only regimen (levonorgestrel, 0.75 mg, repeated in 12 hours) appears t

4 rone, 2.2 (1.5 to 3.2) and 2.3 (1.3 to 3.9); levonorgestrel, 1.7 (1.4 to 2.0) and 2.0 (1.6 to 2.5); n

5 l acetate, 213 events [19.3%] in 1104 women; levonorgestrel, 211 events [18.9%] in 1117 women).

6 ring device offering simultaneous release of levonorgestrel and dapivirine - a lead candidate antiret

7 second-generation progestogens (principally levonorgestrel and norethindrone) continues.

8 ontributors to corticosteroid activities and levonorgestrel as the main contributor to progestogenic

9 Understanding and overcoming this levonorgestrel binding phenomenon is critical for the on

10 to be key parameters impacting the extent of levonorgestrel binding, each through their influence on

11 Secondary endpoints included week 48 levonorgestrel concentrations and unintended pregnancies

12 Week 24 geometric mean levonorgestrel concentrations were 528, 280, and 710 pg/

13 Week 48 levonorgestrel concentrations were 580, 247, and 664 pg/

14 The primary endpoint was week 24 levonorgestrel concentrations, compared between the ART-

15 evirapine-based ART did not adversely affect levonorgestrel exposure or efficacy.

16 Within 1 year of combined use, levonorgestrel exposure was markedly reduced in particip

17 ficacy and safety of ulipristal acetate with levonorgestrel for emergency contraception.

18 e group (1.8%, 95% CI 1.0-3.0) and 22 in the levonorgestrel group (2.6%, 1.7-3.9; odds ratio [OR] 0.6

19 ate group and 35 (2.2%) in 1625 women in the levonorgestrel group (OR 0.58, 0.33-0.99; p=0.046).

20 three pregnancies, all of which were in the levonorgestrel group.

21 l acetate group and a molar pregnancy in the levonorgestrel group.

22 The contraceptive implant Norplant (levonorgestrel) had a fairly short life in the UK.

23 tic analog found in hormonal contraceptives, levonorgestrel, impacts sequential influenza A virus inf

24 Levonorgestrel implants were inserted at baseline in all

25 through their influence on the solubility of levonorgestrel in the silicone elastomer.

26 We aimed to assess whether a levonorgestrel intrauterine system could modulate the ut

27 rveillance before and after insertion of the levonorgestrel intrauterine system for 12 months.

28 el), 1.6 (95% CI, 1.55-1.69); and users of a levonorgestrel intrauterine system, 1.4 (95% CI, 1.31-1.

29 men who require long-term anticoagulation, a levonorgestrel intrauterine system, tranexamic acid (dur

30 proved from baseline to 6 months in both the levonorgestrel-IUS group and the usual-treatment group (

31 al health) were significantly greater in the levonorgestrel-IUS group than in the usual-treatment gro

32 period but were significantly greater in the levonorgestrel-IUS group than in the usual-treatment gro

33 571 women with menorrhagia to treatment with levonorgestrel-IUS or usual medical treatment (tranexami

34 ears, more of the women were still using the levonorgestrel-IUS than were undergoing the usual medica

35 who presented to primary care providers, the levonorgestrel-IUS was more effective than usual medical

36 evonorgestrel-releasing intrauterine system (levonorgestrel-IUS) with usual medical treatment in wome

37 with placebo or one of two progestins, P4 or levonorgestrel (LNG), and infected with a mouse-adapted

38 Some progestins, such as levonorgestrel (LNG), exert androgenic effects in mammal

39 The growing popularity of levonorgestrel (LNG)-releasing intra-uterine systems for

40 200 ng/L P4, RU486, norethindrone (NET), and levonorgestrel (LNG).

41 carrageenan (CG; targets HPV and HSV-2), and levonorgestrel (LNG; targets unintended pregnancy).

42 ature, levonorgestrel particle size, initial levonorgestrel loading and silicone elastomer type were

43 30 mg ulipristal acetate (n=1104) or 1.5 mg levonorgestrel (n=1117) orally.

44 xual intercourse (ulipristal acetate, n=844; levonorgestrel, n=852).

45 , Medroxyprogesterone acetate (MPA), but not Levonorgestrel, Norethisterone or progesterone, suppress

46 The greatest concern is associated with levonorgestrel, norethisterone, and gestodene and their

47 The levonorgestrel-only regimen (levonorgestrel, 0.75 mg, re

48 a single concentration of 100 ng/L of either Levonorgestrel or Gestodene stopped spawning almost comp

49 Cure time, cure temperature, levonorgestrel particle size, initial levonorgestrel loa

50 retroviral therapy (ART) coadministration on levonorgestrel pharmacokinetics.

51 argest randomized, controlled trial to date, levonorgestrel prevented about 85% of pregnancies that w

52 roxyprogesterone acetate (DMPA; n = 32), the levonorgestrel-releasing intrauterine device (LNG-IUD; n

53 lticenter, randomized trial, we compared the levonorgestrel-releasing intrauterine system (levonorges

54 The levonorgestrel-releasing intrauterine system (LNG-IUD),

55 The levonorgestrel-releasing intrauterine system had a prote

56 The levonorgestrel-releasing intrauterine system is consider

57 Levonorgestrel subdermal implants are preferred contrace

58 , the ability of the contraceptive progestin levonorgestrel to bind chemically with hydrosilane group